Table of Contents
- Trial overview
- Who is being studied
- What is being measured
- Trial phase and design
- What this means for patients
Trial overview
This article covers one authorised interventional study of Gonadotropin Releasing Hormone Analogues in men with metastatic castration-sensitive prostate cancer (mCSPC).[1] The study is testing an intermittent androgen deprivation therapy (ADT) approach with apalutamide monotherapy after earlier combination treatment.[1]
The trial asks whether the intermittent approach can keep cancer control similar while lowering the burden of hot flashes.[1] The study is authorised and planned for 521 participants.[1]
Who is being studied
The target population is participants with metastatic castration-sensitive prostate cancer, which means prostate cancer that has spread and still responds to hormone-based treatment.[1] The brief summary also says participants must have reached a PSA level below 0.2 ng/mL after 6 months of apalutamide and ADT combination therapy.[1]
PSA stands for prostate-specific antigen, a blood marker used to follow prostate cancer activity.[1] This means the study is focused on people whose disease responded well enough to earlier treatment to move into the next study step.[1]
What is being measured
The main disease outcome is 18-month radiographic progression-free survival.[1] Radiographic progression-free survival means the time during which scans do not show the cancer getting worse.[1]
The study also measures the 18-month percent change in severity adjusted hot flash score.[1] This score tracks how often hot flashes happen and how strong they are, so the trial can measure symptom burden as well as cancer control.[1]
Trial phase and design
This is a Phase 3 trial.[1] Phase 3 studies usually involve larger groups and are used to compare how well a treatment strategy works in real clinical research settings.[1]
The study type is interventional, which means the researchers assign a treatment plan and then measure the results.[1] In this trial, the plan includes intermittent ADT with apalutamide monotherapy, compared with the study’s main outcome goals.[1]
What this means for patients
For patients, this trial is mainly about finding a treatment pattern that may keep prostate cancer under control while reducing treatment burden.[1] The focus is not only on scan results, but also on day-to-day effects such as hot flashes.[1]
Because only one trial is listed in the source data, the current picture is limited to this specific study in mCSPC.[1] The available data do not provide extra details about other cancer types, other phases, or additional trial endpoints beyond the ones listed here.[1]
